The U.S. Meals and Drug Administration (FDA) has accepted Revuforj (revumenib), which is a menin inhibitor, for the therapy of relapsed or refractory acute myeloid leukemia (AML) with a prone nucleophosmin 1 (NPM1) mutation in grownup and pediatric sufferers 1 12 months outdated and older who don’t have any passable various therapy choices.
The approval was introduced in a information launch issued by the company.
The drug’s effectiveness was decided in a single-arm cohort of the open-label, multicenter SNDX-5613-0700, or AUGMENT-101, medical trial, wherein a prone mutation was confirmed in enrolled sufferers utilizing next-generation sequencing or polymerase chain response of the final exon of NPM1.
Glossary
Full Remission Charge (CR): the proportion of sufferers whose most cancers can now not be detected after therapy.
Full Remission with Partial Hematological Restoration (CRh): most cancers is now not detectable (full remission), however the blood counts — comparable to pink cells, white cells, or platelets — haven’t absolutely returned to regular ranges.
Transfusion Dependence: when an individual wants common blood transfusions (pink cells or platelets) as a result of their physique can’t make sufficient wholesome blood cells by itself.
Differentiation Syndrome: A attainable facet impact of some most cancers therapies that trigger immature most cancers cells to mature (or “differentiate”) rapidly. This sudden change can result in signs comparable to fever, weight acquire, fluid buildup, or respiratory issues.
QTc Interval Prolongation and Torsades de Pointes: These phrases consult with modifications within the coronary heart’s electrical exercise that may be seen on an electrocardiogram (ECG). QTc prolongation means the guts takes barely longer than regular to recharge between beats. Torsades de Pointes is a uncommon however critical kind of irregular coronary heart rhythm that may happen if the QTc turns into too lengthy.
Embryo-Fetal Toxicity: Some medicines can hurt an unborn child if taken throughout being pregnant. That is known as embryo-fetal toxicity.
The principle outcomes of the trial have been full remission price (CR), full remission with partial hematological restoration (CRh), CR and CRh period and the speed of conversion from transfusion dependence to transfusion independence.
The company reported that the CR+CRh price was 23.1% and the median CR+CRh period was 4.5 months, and of the 46 sufferers who have been depending on pink blood cell (RBC) and/or platelet transfusions at baseline, eight (17%) grew to become impartial of RBC and platelet transfusions throughout any 56-day post-baseline interval.
Relating to security, the company famous that the drug’s prescribing info consists of warnings and precautions for differentiation syndrome, QTc interval prolongation and Torsades de Pointes, and embryo-fetal toxicity.
The really useful dosage of Revuforj, the company said, varies by a affected person’s weight and concomitant use of sturdy CYP3A4 inhibitors.
What’s Revuforj and How Does It Work to Deal with AML?
Revuforj, as outlined by the Nationwide Most cancers Institute on its web site, is a drug that binds to a protein known as menin and retains it from binding to a different protein known as KMT2A, and this in flip stops or slows the expansion of leukemia cells with modifications within the KMT2A gene.
It was beforehand
The oral drug was granted precedence assessment by the FDA in June 2025 for the therapy of relapsed or refractory mutant NPM1-positive AML, in line with a information launch from Syndax Prescription drugs, the producer of the drug.
Syndax introduced in September that the Nationwide Complete Most cancers Community (NCCN) Scientific Observe Tips in Oncology (NCCN Tips) for AML have been up to date to incorporate Revuforj as a class 2A suggestion for relapsed or refractory (R/R) acute myeloid leukemia (AML) with an NPM1 mutation (mNPM1), with the replace based mostly on constructive pivotal outcomes from the AUGMENT-101 trial of revumenib which have been printed within the journal Blood earlier this 12 months.
“The inclusion of [Revuforj] as a really useful therapy possibility for R/R NPM-mutated AML within the NCCN Tips underscores the power of our medical knowledge on this inhabitants and additional solidifies [Revuforj’s] main place,” mentioned Nick Botwood, head of analysis and improvement and chief medical officer at Syndax, in a information launch issued on the time. “Given the pivotal function NCCN Tips play in guiding the decision-making course of for clinicians, payers, sufferers and different key stakeholders within the U.S. and past, it is a main milestone for Syndax and your entire acute leukemia group.”
Syndax has said that moreover, a number of trials of Revuforj are ongoing or deliberate throughout the therapy panorama, together with together with customary of care therapies in newly identified sufferers with mNPM1 or KMT2Ar AML.
For extra information on most cancers updates, analysis and training,
References:
- “FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a prone NPM1 mutation,” FDA; https://www.fda.gov/medicine/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation?utm_medium=e mail&utm_source=govdelivery
- “Revuforj,” Nationwide Most cancers Institute; https://www.most cancers.gov/publications/dictionaries/cancer-terms/def/revuforj
- “FDA Approves Revuforj for Relapsed/Refractory Acute Leukemia Subset,” CURE; https://www.curetoday.com/view/fda-approves-revuforj-for-relapsed-refractory-acute-leukemia-subset
- “Syndax’s Revuforj® (revumenib) Included in NCCN Scientific Observe Tips in Oncology (NCCN Tips®) for the Therapy of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia,” information launch; https://ir.syndax.com/news-releases/news-release-details/syndaxs-revuforjr-revumenib-included-nccn-clinical-practice
